SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TELK -- Telik, Inc.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject11/14/2000 10:21:56 PM
From: scaram(o)uche  Read Replies (1) of 887
 
Finally listening to the conference call. There is specific
reference to both the diabetes (TLK 17411) and caspase-3 projects. Just parking....

<TABLE>
<CAPTION>
Product Development Commercialization
Candidate Clinical Indication Status Rights
- ---------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cancer
TLK286 Chemotherapy-resistant Phase I Worldwide
Targeted cancers, including . phase I clinical
chemotherapeutic drug colon, ovarian, lung, trial commenced
pancreas, 1/00
lymphoma/leukemia and
breast

TLK199 Chemotherapy-induced low Pre-IND Worldwide
Bone marrow stimulant white blood cell count, . IND-enabling
or neutropenia studies initiated
6/99
. clinical grade material
prepared 1/00

IGF-1 inhibitor Prostate cancer Lead optimization Worldwide
. small
molecule
inhibitors
discovered
- ---------------------------------------------------------------------------------------------------
Diabetes
Insulin-independent Type 2 diabetes Candidate nomination/lead Worldwide except
insulin receptor optimization Japan and most other
Asian countries
activators . oral activity in animal
models
. preclinical and safety
assessment initiated

Insulin-dependent Type 2 diabetes Candidate nomination/lead Worldwide except
insulin receptor optimization Japan and most other
activators Asian countries
. activity in animal models
. preclinical and safety
assessment initiated
- ---------------------------------------------------------------------------------------------------
Inflammatory disease
MCP-1 antagonist Rheumatoid arthritis, Lead optimization North and South
asthma atherosclerosis, . small America and jointly
multiple sclerosis, molecule in Europe
cancer inhibitors
discovered
. activity in animal models

MIP-1 alpha inhibitor Rheumatoid arthritis, Lead optimization North and South
multiple sclerosis, . small America and jointly
cancer molecule in Europe
inhibitors
discovered

IL-8 inhibitor Rheumatoid arthritis, Lead optimization North and South
nephritis, psoriasis, . small America and jointly
cancer molecule in Europe
inhibitors
discovered
- ---------------------------------------------------------------------------------------------------
Stroke
Caspase-3 inhibitor Stroke Lead optimization Worldwide
. small
molecule
inhibitors
discovered
</TABLE>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext